Print

Cancer Research Consortium of West Michigan

Leukemia Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Narrow List by Age:

Leukemia

Cancer Type: (Ph-) ALL
Research Base: SWOG
Protocol: SWOG S1318

SWOG S1318: A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL. 

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG AALL15P1

COG AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Infants less than 1 year of age on the date of diagnosis are eligible; infants must be >36 weeks gestational age at the time of enrollment.

Cancer Type: Relapsed Refractory CD22 B-ALL
Research Base: COG
Protocol: COG AALL1621

COG-AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) TEMPORARY CLOSURE

Patients must be ≥1 year and < 22 years of age at the time of enrollment.

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG AALL1521

COG-AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia 

Age ≥ 1 year and ≤ 21 years at time of leukemia diagnosis.

Cancer Type: Ph+ ALL
Research Base: COG
Protocol: COG AALL1631

COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone

Age:  > 1 year and < 21 years at ALL diagnosis

Cancer Type: ACUTE MYELOID LEUKEMIA
Research Base: Alliance
Protocol: Alliance A041701

A RANDOMIZED PHASE II/III STUDY OF CONVENTIONAL CHEMOTHERAPY +/- UPROLESELAN (GMI- 1271) IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA RECEIVING INTENSIVE INDUCTION CHEMOTHERAPY

Cancer Type: NEWLY DIAGNOSED PRECURSOR B-CELL ALL
Research Base: Alliance
Protocol: Alliance A041501

A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG ACCL16N1CD
 

COG-ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Cancer Type: Chronic Myeloid Leukemia (CML)
Research Base: SWOG
Protocol: SWOG S1712

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

Cancer Type: Chronic Lymphocytic Leukemia (CLL)
Research Base: Alliance
Protocol: Alliance A041702

 “A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)” 

Cancer Type: B-ALL, B-LLy
Research Base: COG
Protocol: COG AALL1731

COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 days and < 10 years of age (B-ALL patients without DS)

Patients must be ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)

Patients must be ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS) 


 
Cancer Type: B-ALL, B-LLy
Research Base: ECOG-ACRIN
Protocol: COG AALL1732

COG-AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly

Patients must be > 365 days and < 25 years of age

Cancer Type: Myelodysplastic Syndromes
Research Base: ECOG-ACRIN
Protocol: NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: AML
Research Base: COG
Protocol: COG AAML1531

COG-AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Children with Down syndrome > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS)